Percorrer por autor "Carbone, Ana Claudia"
A mostrar 1 - 6 de 6
Resultados por página
Opções de ordenação
- Beauty choices : uncovering the profile of who opts for aesthetic proceduresPublication . Agrizzi, Rafaela Rocha; Peroni, Matheus Bellanda; Gonçalves-Soares, Leticia Machado; Carbone, Ana Claudia; Câmara-Souza, Mariana Barbosa; Sanchez-Ayala, Alfonso; Manso, Ana Cristina; Canales, Giancarlo De la TorreBackground: The demand for aesthetic procedures has increased, driven by advances in aesthetic therapies. Therefore, understanding the factors that influence individuals to undergo aesthetic procedures is important. This study aimed to assess the profile of patients that received or did not receive aesthetic procedures. Methods: This cross-sectional study enrolled 834 female participants aged between 18 and 65 years which were divided in two groups: yes to aesthetic procedures (YAP) and no to aesthetic procedures (NAP). Participants were instructed to fill out a form that included sociodemographic questions, a question regarding performing or not aesthetic procedures and the Portuguese validated versions of five FACE-Q scales. Data were collected electronically from October 2023 to February 2025. For group comparison for continuous variables, the Yuen test was used and Fisher's exact test for categorical variables. Multivariate logistic regression was also performed to assess the influence of variables in performing aesthetic procedures. Results: The sociodemographic data showed group differences in age, education and marital status and income (p < 0.001). Botulinum toxin type A was the most common minimally invasive procedures reported by the participants. Also, volunteers of the YAP group showed greater self-perception and concern about ageing (FACE-Q1 ageing appraisal) (p=0.001). Multivariate logistic regression analysis showed that marital and education status, income and FACE-Q1 influence the decision of performing aesthetic procedures. Conclusion: Women of higher educational level, divorce, with higher income and that present higher concerns about ageing are linked to a greater likelihood of undergoing facial aesthetic procedures.
- Comparing ready-to-use and powder abobotulinumtoxinA for glabellar lines : a randomized, controlled, triple-blinded clinical trialPublication . Silva Junior, Silvio Ventura da; Neves, Maria Luiza Boechat Borges; Sanchez-Ayala, Alfonso; Cebola, Pedro Miguel Teixeira Carvas; Carbone, Ana Claudia; Câmara-Souza, Mariana Barbosa; Poluha, Rodrigo Lorenzi; Canales, Giancarlo De la TorreBackground: Botulinum toxin A (BoNT-A) is the most used procedure to treat glabellar lines; however, limited data exist about the effectiveness of ready-to-use BoNT-A (RTUaboBoNT-A) for this indication. Aims: This study compared the efficacy, durability, and safety of RTUaboBoNT-A for moderate and severe glabellar wrinkles. Methods: This randomized triple-blinded trial included 38 male volunteers aged between 25 and 50 years. Participants were randomly divided into two groups: abobotulinumtoxinA (aboBoNT-A, n = 18) and RTUaboBoNT-A (n = 20). Groups received 10 U for procerus muscle and 20 U for the corrugator muscle. Assessed variables included, electromyography activity (EMG), Merz 5-point glabellar lines scale, FACE-Q appraisal for lines between the eyebrows and Visual Analogue Scale for pain intensity. Assessments were performed before and 1, 2, 3, and 4 months after injections. For differences in EMG and satisfaction scores, the two-way repeated-measures ANOVA and Bonferroni's post hoc analyses were conducted. Wrinkle severity scores were analyzed with the chi-squared test. Results: Inter-group comparisons revealed no significant differences in EMG scores in all assessed periods for the corrugator supercili (p = 0.11) and the procerus muscles (p = 0.93); for severity of glabellar lines, no significant differences were also found in all follow-ups for rest (p = 0.737) and contracted position (p = 0.390), as well as for satisfaction with the treatments. However, the RTUaboBoNT-A group presented higher levels of pain intensity during the injection procedure (p = 0.01). Conclusion: The RTUaboBoNT-A and aboBoNT-A are comparable in efficacy, durability, and safety.
- Efficacy and safety of poly-l-lactic acid in facial aesthetics : a systematic reviewPublication . Signori, Roberta; Barbosa, Antony de Paula; Cezar-dos-Santos, Fernando; Carbone, Ana Claudia; Ventura, Silvio; Nobre, Bryanne Brissian de Souza; Neves, Maria Luiza Boechat Borges; Câmara-Souza, Mariana Barbosa; Poluha, Rodrigo Lorenzi; Canales, Giancarlo De la TorreThe primary objective of this systematic review study was to investigate the effectiveness, durability, and adverse events of PLLA treatment for aesthetic indications. The search strategy was performed in MEDLINE (Ovid). The electronic literature search of five databases was performed, from the inception of the databases until the 12th of February 2024. This was to identify randomized clinical trials that assessed PLLA treatment in adult individuals exhibiting facial aging and/or facial lipoatrophy. Risk of bias was assessed using the Cochrane Risk-of-Bias Tool for Randomized Trials (RoB 2). Eleven RCTs out of 1467 identified citations were included. Four studies showed increased dermal thickness, significant improvement in facial lipoatrophy severity and aesthetic clinical scores, after PLLA treatment with its effects sustained for at least 25 months. Two studies demonstrated the superiority of PLLA over injectable human collagen. Also, three studies showed positive results favoring PLLA when compared with PH gel in lipoatrophy severity, transepidermal water loss, skin quality, elasticity, and patient satisfaction. All adverse events were mild-to-moderate in intensity, and the main ones worth noting were bruising, hematoma, tenderness, nodules, and edema. Five out of eleven studies were considered having high risk of bias. The evidence on the effectiveness and safety of PLLA for facial rejuvenation is of low quality; thus, the reported high effectiveness, safety, and long-lasting effects for this purpose should be further investigated.
- Exploring botulinum toxin’s impact on masseter hypertrophy : a randomized, triple-blinded clinical trialPublication . Nobre, Bryanne Brissian de Souza; Rezende, Luciana; Câmara-Souza, Mariana Barbosa; Sanchez-Ayala, Alfonso; Blass, Rodrigo; Carbone, Ana Claudia; Manso, Ana Cristina; Ernberg, Malin; Christidis, Nikolaos; Canales, Giancarlo De la TorreThe present study aimed to assess the effectiveness and functional adverse effects of a single and multiple injections of botulinum toxin A (BoNT-A) for masseter hypertrophy (MH). Twenty-six women complaining about lower third facial enlargement due to MH, received 75 U of BoNT-A (abobotulinum toxin) in each masseter muscles. After 3 months, patients were randomly assigned to receive a second treatment session of Saline Solution: (G1; n = 11) or BoNT-A: (G2; n = 12). Muscle thickness (ultrasound), electrical activity (electromyography; EMG), masticatory performance, and subjective perception of MH were evaluated. Follow-up was performed at 1, 3 and 6 months. Muscle thickness, EMG activity, and masticatory performance were analyzed using ANOVA two-way and Sidak test as post-hoc. Masticatory performance was analyzed by the Friedman’s test and Mann–Whitney test. Regarding inter-groups comparisons, there was a significant decrease in the left masseter muscle thickness in the G2 group at the 6 month follow-up (p < 0.02). For EMG, significant differences were evident at the 6 month assessment, with higher masseter activity for G1 (p < 0.05). For masticatory performance, no significant differences were observed throughout the study (p > 0.05) and a higher improvement in subjective perception of MH was observed in the 1 month follow-up for G2 (p < 0.05). In conclusion, BoNT-A is effective for MH, however multiple injections cause functional adverse effects in masseter muscle.
- High levels of physical activity reduce the esthetic durability of botulinum toxin type A : a controlled single-blind clinical trialPublication . Morhy, Omar Neves; Sisnando, Andréa Lisbôa; Câmara-Souza, Mariana Barbosa; Carbone, Ana Claudia; Canales, Giancarlo De la TorreThe present study aimed to evaluate the influence of physical activity on the durability of the esthetic effect of botulinum toxin type A (BoNT-A). Sixty female patients were allocated to three groups (n = 20) according to their physical activity level (PA): Low PA, Moderate PA, and High PA. All groups received a single injection of onabotulinumtoxinA, considering standardized doses in the frontalis (12U), corrugator supercilia (7U, each), and procerus muscles (4U). Outcomes were measured using electromyography (EMG), Merz 5-point scales, and Face-Q scales (perceived age and lines between eyebrows). A follow-up occurred after 30, 60, and 90 days. EMG results showed a significant decrease in muscle activity in the Low-PA group at all follow-ups compared with the other groups (p < 0.001). The Merz scale scores showed that the severity of forehead and glabellar lines significantly improved in the Low-PA group throughout this study compared with the other groups (p < 0.001). No significant differences between groups were found in the Face-Q scale for perceived age, while the Face-Q scale for lines between eyebrows showed better results for Low-PA (p < 0.01) and Moderate-PA (p < 0.01) groups compared to the High-PA group at the 30- and 90-day follow-ups. The durability of the esthetic effect of BoNT-A seems to be negatively influenced by the level of physical activity.
- Temporalis muscle changes following botulinum toxin A injections in masseter hypertrophy patients : a randomized triple-blinded trialPublication . Nobre, Bryanne B. de Souza; Machado, Luciana de Oliveira Resende; Poluha, Rodrigo Lorenzi; Câmara-Souza, Mariana Barbosa; Carbone, Ana Claudia; Almeida, Andre Mariz de; Grigoriadis, Anastasios; Kumar, Abhishek; Canales, Giancarlo De la TorreBackground: This study aimed to elucidate the effects of botulinum toxin A (BoNT-A) treatment for patients diagnosed with masseter hypertrophy on the temporalis muscle, with a particular focus on assessing alterations in muscle thickness, electromyographic (EMG) activity, and the development of muscle pain. Methods: The present randomized triple-blinded clinical trial enrolled 26 female participants aged between 25 and 50 years complaining about masseter hypertrophy. Participants received 75U of BoNT-A (abobotulinumtoxinA) in both masseter muscles and after three months were randomized to receive a second treatment session of saline solution (S-BoNT-A) or BoNT-A (M-BoNT-A). Longitudinal assessments included temporalis muscle thickness through ultrasound, EMG activity, subjective pain, and masseter prominence severity after one, three, and six months of the first injection session. Muscle thickness, EMG, and subjective pain were analysed using two-way ANOVA with repeated measures and post hoc Sidak test, and for masseter prominence severity, Friedman and Mann–Whitney tests were used. Results: Regarding inter-group comparisons, a higher muscle thickness (p < 0.02) and a higher EMG activity (p < 0.01) were found in the M-BoNT-A group at the 6-month follow-up. For subjective pain assessments, inter-group comparisons showed a higher prevalence of painful regions in M-BoNT-A group at the 6-month follow-up (p < 0.02). No significant differences were found in masseter prominence severity at the 6 months assessment between groups. Conclusion: BoNT-A treatment for masseter hypertrophy lead to structural and functional changes in the temporalis muscle, presenting higher changes after multiple injections of this treatment.